Skip to content

Cost-effectiveness of a ketogenic diet in children with intractable epilepsy: a Dutch randomized controlled trial

Cost-effectiveness of a ketogenic diet in children with intractable epilepsy: a Dutch randomized controlled trial - Cost-effectiveness ketogenic diet/COEK study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON34955
Enrollment
50
Registered
2010-07-02
Start date
2010-07-26
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy or seizure attacks

Interventions

Description of the ketogenic diet: The ketogenic diet is introduced during a hospitalization for one week or longer if medically indicated. The diet is calculated on an individual basis by the dieti

Sponsors

Epilepsiecentrum Kempenhaeghe
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male and female children with uncontrolled seizures, aged between 1-18 years who are not eligible for epilepsy surgery.

Exclusion criteria

Exclusion criteria: The following medical contraindications of the ketogenic diet are criteria for exclusion: • Fatty acid oxidation disorders and related diseases • Diabetes and hyperinsulinism • Prolonged QT-time syndrome • Hypercholesterolemia, hypertriglyceridemia • Severe liver, kidney or pancreas diseases • Renal tubular acidosis • Treatment with topiramate or acetazolamide and a positive family history or other risk factors for kidney stones or acidosis • Severe behavioural disorder • Malnutrition

Design outcomes

Primary

MeasureTime frame
Clinical outcome: proportion of children with a 50% or more reduction in seizure frequency. Economic evaluation: • Quality of life and quality adjusted life years (QALYs). • Societal costs

Secondary

MeasureTime frame
The secondary parameters are: • Mean number of seizures as a percentage of the number of seizures during the 4-week baseline period. • Seizure severity: National Hospital Seizure Severity Scale (NHS3). • Side effects/complaints: Side Effects of Anti-Epileptic Drugs questionnaire (SIDEAD). • Psychological assessment : o Cognition o Behavioural and social-emotional functioning o Psychosocial adjustment

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)